Navigation Links
MicroDose Announces Positive Results From the QDose Inhaled Insulin Glucose Clamp Study
Date:8/19/2007

MONMOUTH JUNCTION, N.J., Aug. 6 /PRNewswire/ -- MicroDose Technologies, Inc., a privately held drug delivery and specialty pharmaceuticals company, today announces top line results from a glucose clamp study of the QDose inhaled insulin product. MicroDose, through its joint venture with Vectura Group plc, QDose Limited, has developed a highly efficient, rapid acting, insulin inhaler, based upon MicroDose's proprietary electronic inhaler technology and Vectura's dry powder insulin formulation. The QDose inhaled insulin product offers dose titration capability over a broad range of dose strengths, in a single inhalation. The inhaler also provides active dose feedbacks to the patient in an easy to use, pocket-sized device.

(Logo: http://www.newscom.com/cgi-bin/prnh/20070803/NYF045LOGO )

The study employed the widely used and validated glucose clamp technique, and results demonstrated that:

-- The inhaled insulin formulation was safe and effective

-- Peak levels of insulin activity were achieved more quickly following

the inhaled insulin than those from the subcutaneous insulin injection

-- Relative bioavailability of inhaled insulin was approximately 18%

during the 3 hour period following dosing; higher than the published

values for the currently marketed inhalation product

-- Administration of the same total dose of inhaled insulin from either a

single blister or two "half strength" blisters led to equivalent

activity; an advantage over the currently marketed inhalation product

The study was a randomized, crossover, open-label glucose clamp study, designed to confirm the high relative bioavailability of the QDose insulin formulation previously observed, and to demonstrate the product's dose titration capability. The results confirmed the faster onset of action seen with the QDose inhaled formu
'/>"/>

SOURCE MicroDose Technologies, Inc.

Copyright©2007 PR Newswire.

Page: 1 2 3 4

Related medicine technology :

1. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
2. Sygnis Pharma AG announces date for presentation of clinical results
3. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
4. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
5. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
6. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
7. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
8. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
9. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
10. Protox Announces Positive Clinical Data from Prostate Cancer Study
11. Inspire Announces Webcast of Presentation at C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/16/2008)... May Offer Novel Approach to Blood ...6 /- Pharmacopeia (Nasdaq:,...nt of novel small,molecule therapeutics, announced...ng Receptor Antagonist (DARA), showed statisticall... 2a study in patients with mild to,moderate hypert...
(Date:5/15/2008)...wswire/ -- Eisai Corporation of North,America anno...tracts about,compounds in the company,s oncology p...y research have been accepted for presentation at ... Clinical Oncology (ASCO),taking place in Chicago...abstracts on Eisai marketed products and,investiga...
(Date:5/15/2008)...light safety profile of BSI-201 in ... Calif., May 15 /- BiPar Sciences, In...eloping novel cancer therapies,today announced th...1, will,be presented at the 2008 American Society ...Findings will be presented from the first in human...
(Date:5/15/2008)...wswire-FirstCall/ -- Cytopia Limited,(ASX: CYT) to...ral,presentation on CYT997 at the 2008 Annual Meet...ASCO) will be accessible to the public via ASCO,s,...ay 15 May (US EDT)., The oral presentation, entit...ic and vascular disrupting agent, in patients with...
Breaking Medicine Technology:Pharmacopeia's First-in-Class Investigational Therapy PS433540 Achieves Statistically Significant Reductions in Blood Pressure in Hypertensive Patients 2Pharmacopeia's First-in-Class Investigational Therapy PS433540 Achieves Statistically Significant Reductions in Blood Pressure in Hypertensive Patients 3Pharmacopeia's First-in-Class Investigational Therapy PS433540 Achieves Statistically Significant Reductions in Blood Pressure in Hypertensive Patients 4Pharmacopeia's First-in-Class Investigational Therapy PS433540 Achieves Statistically Significant Reductions in Blood Pressure in Hypertensive Patients 5Pharmacopeia's First-in-Class Investigational Therapy PS433540 Achieves Statistically Significant Reductions in Blood Pressure in Hypertensive Patients 6Pharmacopeia's First-in-Class Investigational Therapy PS433540 Achieves Statistically Significant Reductions in Blood Pressure in Hypertensive Patients 7Pharmacopeia's First-in-Class Investigational Therapy PS433540 Achieves Statistically Significant Reductions in Blood Pressure in Hypertensive Patients 8Eisai's Commitment to Oncology Demonstrated by Clinical Data to be Presented at ASCO Annual Meeting 2Eisai's Commitment to Oncology Demonstrated by Clinical Data to be Presented at ASCO Annual Meeting 3Eisai's Commitment to Oncology Demonstrated by Clinical Data to be Presented at ASCO Annual Meeting 4Eisai's Commitment to Oncology Demonstrated by Clinical Data to be Presented at ASCO Annual Meeting 5Eisai's Commitment to Oncology Demonstrated by Clinical Data to be Presented at ASCO Annual Meeting 6Eisai's Commitment to Oncology Demonstrated by Clinical Data to be Presented at ASCO Annual Meeting 7Eisai's Commitment to Oncology Demonstrated by Clinical Data to be Presented at ASCO Annual Meeting 8BiPar Sciences Announces Clinical Data Presentations on Lead PARP Inhibitor, BSI-201, at 40th American Society of Clinical Oncology Annual Meeting 2No strong evidence linking amateur boxing with long term brain injury 3021 1No strong evidence linking amateur boxing with long term brain injury 3021 2Caraco Pharmaceutical Laboratories Ltd Announces Tentative FDA Approval for Generic Zyrtec Chewable 28R 29 3018 1Caraco Pharmaceutical Laboratories Ltd Announces Tentative FDA Approval for Generic Zyrtec Chewable 28R 29 3018 2Story ideas from Molecular 26amp 3B Cellular Proteomics 701 1Story ideas from Molecular 26amp 3B Cellular Proteomics 701 2Story ideas from Molecular 26amp 3B Cellular Proteomics 701 3Story ideas from Molecular 26amp 3B Cellular Proteomics 701 4Study Rates Heart Health of Popular Diet Plans 3010 1Study Rates Heart Health of Popular Diet Plans 3010 2Study Rates Heart Health of Popular Diet Plans 3010 3Study Rates Heart Health of Popular Diet Plans 3010 4
...ciences, Ace393, the World,s First Commercial Vacc...ter Successfully,Completes Phase I Clinical Trials...immunogenicity , ODENSE, Denmark, March 28, 2007 -...ny is pleased to announce the successful,completio...,ACE393, the world,s first commercial vaccine for...
...ilot Study Demonstrates 50% Survival in Valortim-T...d., March 29, 2007,/PRNewswire-FirstCall/ -- Medar...and PharmAthene, Inc., a privately held,biotechnol...ense,countermeasures, today announced that Valorti...andidate being developed for the,prevention and tr...
Other Medicine Technology:Ace Biosciences, Ace393, the World's First Commercial Vaccine for,Travellers' Diarrhoea Caused by Campylobacter Successfully,Completes Phase I Clinical Trials 2Ace Biosciences, Ace393, the World's First Commercial Vaccine for,Travellers' Diarrhoea Caused by Campylobacter Successfully,Completes Phase I Clinical Trials 3Ace Biosciences, Ace393, the World's First Commercial Vaccine for,Travellers' Diarrhoea Caused by Campylobacter Successfully,Completes Phase I Clinical Trials 4Anthrax Monoclonal Antibody Valortim Demonstrates Therapeutic,Effect in New Primate Model of Established Anthrax Infection 2Anthrax Monoclonal Antibody Valortim Demonstrates Therapeutic,Effect in New Primate Model of Established Anthrax Infection 3Anthrax Monoclonal Antibody Valortim Demonstrates Therapeutic,Effect in New Primate Model of Established Anthrax Infection 4Anthrax Monoclonal Antibody Valortim Demonstrates Therapeutic,Effect in New Primate Model of Established Anthrax Infection 5Anthrax Monoclonal Antibody Valortim Demonstrates Therapeutic,Effect in New Primate Model of Established Anthrax Infection 6Anthrax Monoclonal Antibody Valortim Demonstrates Therapeutic,Effect in New Primate Model of Established Anthrax Infection 7Anthrax Monoclonal Antibody Valortim Demonstrates Therapeutic,Effect in New Primate Model of Established Anthrax Infection 8
(Date:5/16/2008)... Month-long Campaign to Emphasize the Importance... 16 /PRNewswire/ -- National dental insurer United...nth, a collaboration,between Oral Health America a... the importance of oral health to overall health. ...n the United States for the first time,making it ...
(Date:5/16/2008)... , (Washington) Declaring that Primary care medi...D, FACP, president of the American College of Phys...atives of employers and consumers to issue a call ...retain general internists and other primary care p...tate of primary care medicine in the U.S., Dr. Dal...
(Date:5/16/2008)... Live Web Cast Scheduled for May 19 at 10:...re-FirstCall/ - Response Biomedical,Corporation (T...ne Kay,Chief Executive Officer, is scheduled to p...ealthcare Conference on Monday May 19th at 10:15 a...l be available on the Company,s,Web site at, http:...
(Date:5/16/2008)... HARRISBURG, Pa., May 16 /PRNewswire-USNewswi...4, is an opportunity to highlight the dedication,o...re citizens to become,trained EMS volunteers, acco...son., This year,s theme, "EMS: Your Life is Our M...ncy is or when it occurs, EMS is there to provide,...
Breaking Medicine News(10 mins):Health News:United Concordia Dental Celebrates National Smile Month 2Health News:ACP says major system reforms needed to improve the state of primary care medicine in the US 2Health News:Response Biomedical Corporation to Present at Rodman & Renshaw 5th Annual Global Healthcare Conference 2Health News:PA Secretary of Health Announces 'Emergency Medical Services Week,' May 18 - 24 2
...n has been getting a princess' treatment in jail f...ing to inmates, the 26-year-old is living in 'Lean...ast beef, spaghetti and meatballs, chicken nuggets...ever get. The jailbird has recently been shifted ...
...gravy, carnation and herb salad, nasturtium sauce ...ls are on the plate . "Flowers have been used for...very secondary way", culinary historian Patrick Ra...r example flowers would be strewn on the floor dur...
...d a law to ban circuses from importing or exportin...tion of animal rights, a legislator said Friday . ...d late Thursday, all imports and exports of animal...nd monkeys are prohibited unless they are needed f...
...drugs and risky sexual behaviour are providing fue...nment advisory body report said Friday . Sexual h...n the last 12 years, and media coverage of celebri... the problem worse, the Independent Advisory Group...
Other Medicine News:Health News:Flower-power on a Plate in Paris 2Health News:Drink and Drugs 'fuel British Sexual Health Crisis' 2
SOLOS Endoscopy shares your commitment to provide every patient with the highest quality care available through our ongoing research and development of advanced surgical instruments and diagnostic so
Operate with confidence. Autosuture is advancing the sate of both open and minimally invasive surgery by providing surgical tools that feel right, function right, and facilitate the right outcome eve
Operate with confidence. Autosuture is advancing the sate of both open and minimally invasive surgery by providing surgical tools that feel right, function right, and facilitate the right outcome eve
Operate with confidence. Autosuture is advancing the sate of both open and minimally invasive surgery by providing surgical tools that feel right, function right, and facilitate the right outcome eve
Medicine Products: